{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T02:10:33Z","timestamp":1790820633429,"version":"4.1.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,21]],"date-time":"2021-10-21T00:00:00Z","timestamp":1634774400000},"content-version":"am","delay-in-days":293,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.diagmicrobio.2020.115225","type":"journal-article","created":{"date-parts":[[2020,9,28]],"date-time":"2020-09-28T11:52:23Z","timestamp":1601293943000},"page":"115225","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Clindamycin combination treatment for the treatment of bone and joint infections caused by clindamycin-susceptible, erythromycin-resistant Staphylococcus spp."],"prefix":"10.1016","volume":"99","author":[{"given":"Agathe","family":"Bonnaire","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Vernet-Garnier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Lebrun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Odile","family":"Bajolet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgane","family":"Bonnet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxime","family":"Hentzien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Ohl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saidou","family":"Diallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Firouz\u00e9","family":"Bani-Sadr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diagmicrobio.2020.115225_bb0005","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1111\/j.1469-0691.2007.01691.x","article-title":"Treatment of staphylococcal prosthetic joint infections with debridement, prosthesis retention and oral rifampicin and fusidic acid","volume":"13","author":"Aboltins","year":"2007","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.diagmicrobio.2020.115225_bb0010","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1111\/bjd.17265","article-title":"Long-term clinical safety of clindamycin and rifampicin combination for the treatment of hidradenitis suppurativa. A critically appraised topic","volume":"180","author":"Albrecht","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.diagmicrobio.2020.115225_bb0015","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1128\/AAC.33.2.245","article-title":"In vitro interaction between rifampin and clindamycin against pathogenic coagulase-negative staphylococci","volume":"33","author":"Arditi","year":"1989","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2020.115225_bb0020","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jinf.2015.09.015","article-title":"Clindamycin and rifampicin: no bull's eye without a target","volume":"72","author":"B\u00e9raud","year":"2016","journal-title":"J Infect"},{"key":"10.1016\/j.diagmicrobio.2020.115225_bb0025","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1111\/j.1365-2125.2012.04292.x","article-title":"Population pharmacokinetics of clindamycin orally and intravenously administered in patients with osteomyelitis: clindamycin population pharmacokinetics in osteomyelitis patients","volume":"74","author":"Bouazza","year":"2012","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.diagmicrobio.2020.115225_bb0030","doi-asserted-by":"crossref","first-page":"962","DOI":"10.3109\/00365548.2011.608082","article-title":"Efficacy of a combined oral clindamycin\u2013rifampicin regimen for therapy of staphylococcal osteoarticular infections","volume":"43","author":"Czekaj","year":"2011","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2020.115225_bb0035","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1093\/jac\/48.2.315","article-title":"Clindamycin treatment of Staphylococcus aureus expressing inducible clindamycin resistance","volume":"48","author":"Drinkovic","year":"2001","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2020.115225_bb0040","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.medmal.2008.06.030","article-title":"Traitement des infections ost\u00e9oarticulaires par clindamycine chez l'adulte","volume":"38","author":"El Samad","year":"2008","journal-title":"M\u00e9decine Mal Infect"},{"key":"10.1016\/j.diagmicrobio.2020.115225_bb0045","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1128\/AAC.01504-08","article-title":"Long-term follow-up trial of oral rifampin-cotrimoxazole combination versus intravenous cloxacillin in treatment of chronic staphylococcal osteomyelitis","volume":"53","author":"Euba","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2020.115225_bb0050","unstructured":"EUCAST. The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 9.0, 2019. http:\/\/www.eucast.org."},{"key":"10.1016\/j.diagmicrobio.2020.115225_bb0055","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1128\/AAC.29.4.611","article-title":"Serum bactericidal activity of rifampin in combination with other antimicrobial agents against Staphylococcus aureus","volume":"29","author":"Hackbarth","year":"1986","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2020.115225_bb0060","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/jac\/dkt374","article-title":"Oral antibiotic treatment of staphylococcal bone and joint infections in adults","volume":"69","author":"Kim","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2020.115225_bb0065","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1086\/324626","article-title":"Mechanisms of resistance to macrolides and lincosamides: nature of the resistance elements and their clinical implications","volume":"34","author":"Leclercq","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2020.115225_bb0070","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.ijantimicag.2016.05.021","article-title":"Short- versus long-duration levofloxacin plus rifampicin for acute staphylococcal prosthetic joint infection managed with implant retention: a randomised clinical trial","volume":"48","author":"Lora-Tamayo","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.diagmicrobio.2020.115225_bb0075","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1111\/j.1469-0691.2009.02761.x","article-title":"Efficacy and tolerance of rifampicin\u2013linezolid compared with rifampicin\u2013cotrimoxazole combinations in prolonged oral therapy for bone and joint infections","volume":"15","author":"Nguyen","year":"2009","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.diagmicrobio.2020.115225_bb0080","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/cis803","article-title":"Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America","volume":"56","author":"Osmon","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2020.115225_bb0085","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1093\/jac\/44.4.581","article-title":"Should clindamycin be used as treatment of patients with infections caused by erythromycin-resistant staphylococci?","volume":"44","author":"Panagea","year":"1999","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2020.115225_bb0090","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1093\/jac\/45.5.715","article-title":"Should clindamycin be used in treatment of patients with infections caused by erythromycin-resistant staphylococci?","volume":"45","author":"Rao","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2020.115225_bb0095","doi-asserted-by":"crossref","first-page":"5957","DOI":"10.1128\/AAC.00463-16","article-title":"Modulation of Staphylococcus aureus biofilm matrix by subinhibitory concentrations of clindamycin","volume":"60","author":"Schilcher","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2020.115225_bb0100","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1086\/377501","article-title":"Failure of clindamycin treatment of methicillin-resistant Staphylococcus aureus expressing inducible clindamycin resistance in vitro","volume":"37","author":"Siberry","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2020.115225_bb0105","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ijantimicag.2008.08.029","article-title":"Comparison of biofilm-associated cell survival following in vitro exposure of meticillin-resistant Staphylococcus aureus biofilms to the antibiotics clindamycin, daptomycin, linezolid, tigecycline and vancomycin","volume":"33","author":"Smith","year":"2009","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.diagmicrobio.2020.115225_bb0110","unstructured":"Soci\u00e9t\u00e9 de Pathologie Infectieuse de Langue Fran\u00e7aise (SPILF), Coll\u00e8ge des Universitaires de Maladies Infectieuses et Tropicales (CMIT), Groupe de Pathologie Infectieuse P\u00e9diatrique (GPIP), Soci\u00e9t\u00e9 Fran\u00e7aise d'Anesth\u00e9sie et de R\u00e9animation (SFAR), Soci\u00e9t\u00e9 Fran\u00e7aise de Chirurgie Orthop\u00e9dique et Traumatologique (SOFCOT), Soci\u00e9t\u00e9 Fran\u00e7aise d'Hygi\u00e8ne Hospitali\u00e8re (SFHH), et al. [Recommendations for clinical practice. Osteo-articular infection therapy according to materials used (prosthesis, implants, osteosynthesis)]. Med Mal Infect 2009; 39:745\u2013774."},{"key":"10.1016\/j.diagmicrobio.2020.115225_bb0115","unstructured":"SOCIETE FRANCAISE DE MICROBIOLOGIE. Comit\u00e9 de l'antibiogramme de la Soci\u00e9t\u00e9 Fran\u00e7aise de Microbiologie\u2014recommandations 2019 V.2.0 Mai."},{"key":"10.1016\/j.diagmicrobio.2020.115225_bb0120","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1111\/j.1469-0691.2006.01463.x","article-title":"Treatment of acute post-surgical infection of joint arthroplasty","volume":"12","author":"Soriano","year":"2006","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.diagmicrobio.2020.115225_bb0125","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ijantimicag.2019.06.006","article-title":"High-dose trimethoprim-sulfamethoxazole and clindamycin for Staphylococcus aureus endocarditis","volume":"54","author":"Tissot-Dupont","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.diagmicrobio.2020.115225_bb0130","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1097\/INF.0b013e3181c35cc5","article-title":"Macrolide-inducible resistance to clindamycin and the D-test","volume":"28","author":"Woods","year":"2009","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.diagmicrobio.2020.115225_bb0135","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/tpj.2016.61","article-title":"HLA-B*51:01 is strongly associated with clindamycin-related cutaneous adverse drug reactions","volume":"17","author":"Yang","year":"2017","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.diagmicrobio.2020.115225_bb0140","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1128\/AAC.01081-09","article-title":"Continuous clindamycin infusion, an innovative approach to treating bone and joint infections","volume":"54","author":"Zeller","year":"2010","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889320306027?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889320306027?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T09:55:41Z","timestamp":1760003741000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0732889320306027"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S0732889320306027"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2020.115225","relation":{},"ISSN":["0732-8893"],"issn-type":[{"value":"0732-8893","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clindamycin combination treatment for the treatment of bone and joint infections caused by clindamycin-susceptible, erythromycin-resistant Staphylococcus spp.","name":"articletitle","label":"Article Title"},{"value":"Diagnostic Microbiology and Infectious Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2020.115225","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115225"}}